Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q3 2026
NewAmsterdam Pharma Co N.V. (NAMS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
NewAmsterdam Pharma Co N.V. (NAMS) reported revenue of $19.2M for the third quarter 2026 (Q3 2026), up 55-fold from a year earlier and +418% from the quarter before. Operating margin was -230.6%, net loss $17.4M (90.7% of revenue).
NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.2M | +418% | 55× |
| Operating profit | −$44.2M | — | — |
| Net earnings | −$17.4M | — | — |
| Operating cash flow | −$39.8M | — | — |
What changed
Revenue was $19.2M in Q3 2026, up 5407% year over year and up 418% from the previous quarter.
Operating costs exceeded revenue by $44.2M, an operating margin of -230.6%. Total costs grew 14% against revenue growth of 5407%. The fastest-growing cost line was Research & development (+27%). The quarter ended with a net loss of $17.4M, narrower than the previous quarter's $64.1M loss. Non-operating items added $28.0M, -173% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$39.8M. Non-cash charges added back $67K of depreciation and amortization and $12.5M of share-based compensation. Working capital and other items used $35.0M. Capital expenditures of $177K exceeded it, leaving free cash flow of −$40.0M.
Questions
What was NewAmsterdam Pharma Co N.V.'s revenue in the third quarter 2026?
NewAmsterdam Pharma Co N.V.
Was NewAmsterdam Pharma Co N.V. profitable in the third quarter 2026?
Operating loss was $44.2M (-230.6% of revenue) and net loss $17.4M.